Krystal Biotech, Inc. $KRYS Position Trimmed by GW&K Investment Management LLC

GW&K Investment Management LLC trimmed its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 65.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,492 shares of the company’s stock after selling 19,683 shares during the quarter. GW&K Investment Management LLC’s holdings in Krystal Biotech were worth $1,852,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Soleus Capital Management L.P. boosted its stake in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares during the period. Braidwell LP increased its stake in shares of Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after acquiring an additional 327,067 shares during the last quarter. Norges Bank acquired a new position in shares of Krystal Biotech in the second quarter worth $38,861,000. First Trust Advisors LP raised its holdings in shares of Krystal Biotech by 571.3% during the second quarter. First Trust Advisors LP now owns 222,370 shares of the company’s stock worth $30,567,000 after acquiring an additional 189,245 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Krystal Biotech by 10.5% during the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $253.69 on Friday. The company has a market capitalization of $7.42 billion, a price-to-earnings ratio of 37.04 and a beta of 0.49. The stock’s 50 day simple moving average is $269.86 and its 200 day simple moving average is $218.28. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. On average, analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This represents a 39.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Janney sold 37,895 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 129,164 shares of company stock valued at $34,538,578. 13.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on KRYS shares. Citigroup boosted their target price on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 18th. Chardan Capital increased their price objective on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.